Arcturus Therapeutics (NASDAQ:ARCT) Given New $60.00 Price Target at HC Wainwright

Arcturus Therapeutics (NASDAQ:ARCT) had its price objective trimmed by HC Wainwright from $63.00 to $60.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently commented on the stock. BTIG Research began coverage on shares of Arcturus Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price target for the company. Wells Fargo & Company reduced their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Buy” and an average price target of $61.40.

Arcturus Therapeutics Price Performance

ARCT stock opened at $14.55 on Friday. The company has a fifty day moving average price of $16.95 and a 200 day moving average price of $18.59. Arcturus Therapeutics has a 12 month low of $14.11 and a 12 month high of $45.00. The company has a market cap of $394.12 million, a price-to-earnings ratio of -6.55 and a beta of 2.96.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. As a group, analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently bought and sold shares of ARCT. Virtus ETF Advisers LLC increased its holdings in shares of Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 1,132 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Arcturus Therapeutics in the 4th quarter valued at about $71,000. National Bank of Canada FI increased its holdings in shares of Arcturus Therapeutics by 639.6% in the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 4,784 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Arcturus Therapeutics by 22.7% in the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 2,036 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new position in shares of Arcturus Therapeutics in the 4th quarter valued at about $200,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.